A recently published study found that a blend of Citrus bergamia and Cynara cardunculus extracts supported vascular inflammation and oxidative stress in subjects with type 2 diabetes and non-alcoholic fatty liver disease.
Image courtesy of DolCas Biotech
A recently published study1 found that a synergistic extract of Citrus bergamia and Cynara cardunculus (Bergacyn, marketed by DolCas Biotech; Landing, NJ) supported vascular inflammation and oxidative stress in subjects with type 2 diabetes and non-alcoholic fatty liver disease. In the randomized, double-blind, placebo-controlled study, 80 subjects were divided into four groups, and given either placebo, 600 mg of Bergacyn, 600 mg of a standalone bergamot extract, or 600 mg of a standalone cynara extract blend.
Results showed that Bergacyn significantly reduced the measures of liver damage enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) by 18 and 15 points, respectively, compared to a 10-point average reduction in the stand-alone groups, and no change in the placebo group. Bergacyn also improved markers of oxidative stress, reduced inflammatory markers, and improved endothelial function compared to the placebo group.
“Bergacyn’s unique blending of a high-polyphenol extract of bergamot and a high-sesquiterpene extract of artichoke leaf showed a novel synergistic benefit that was more than additive, when compared to stand-alone, single doses of bergamot or cynara extract,” explains Dr. Shavon Jackson-Michel, director of medical and scientific affairs for DolCas. “The potentizing action as a function of the patented process used enhances Bergacyn’s bioactivity.”
1. Musolino V et al. “The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease.” Journal of Traditional and Complementary Medicine, Published online ahead of print on February 8, 2020
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.